Niemann-Pick disease, type C1 (NPC1) is a neurodegenerative, lysosomal storage disorder due to mutation of the NPC1 gene. The NPC1 phenotype is characterized by progressive neuronal dysfunction, including cerebellar ataxia and dementia. There is histological evidence of neuroinflammation and progressive neuronal loss, with cerebellar Purkinje cells particularly vulnerable to loss of NPC1 function. Necroptosis was evaluated as a mechanism of neuronal loss. Receptor-interacting protein kinase 1 (RIP1) and RIP3 are key components of the necrosomal complex that regulates necroptotic cell death. We report increased expression of RIP1 and RIP3 in NPC1 fibroblasts, NPC1 iPS cell-derived neuronal precursors, and in cerebellar tissue from both NPC1 mice and patients. Our data suggest a positive correlation between NPC1 neurological disease severity and assembly of the necrosome complex. Furthermore, we demonstrate that pharmacological inhibition of RIP1 decreases cell death both in vitro and in vivo. Treatment of Npc1-mutant mice with necrostatin-1, an allosteric inhibitor of RIP1, significantly delayed cerebellar Purkinje cell loss, progression of neurological symptoms, and death. Collectively, our data identified necroptosis as a key component of the molecular network that contributes to neuronal loss in NPC1 and establish that inhibition of necroptosis is a potential therapeutic intervention.
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Treatment of Npc1-mutant mice with necrostatin-1, an allosteric inhibitor of RIP1, significantly delayed cerebellar Purkinje cell loss, progression of neurological symptoms, and death. Collectively, our data identified necroptosis as a key component of the molecular network that contributes to neuronal loss in NPC1 and establish that inhibition of necroptosis is a potential therapeutic intervention.
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Niemann-Pick disease, type C (NPC) is a rare, inherited, neurovisceral, lysosomal storage disorder. The incidence of classical NPC has been estimated to be on the order of 1/100,000, while there may be a more frequent late-onset variant. 1,2 NPC can be caused by mutation in either NPC1 or NPC2, with the majority of cases (~95%) being due to mutation of NPC1.
1 Impaired function of either NPC1 or NPC2 results in the endolysomal storage of unesterified cholesterol and other lipids. 1, 3, 4 The NPC1 phenotype is heterogeneous with respect to both age of onset (infantile, childhood, adolescent, adult) and disease manifestations. Neurological manifestations are typically associated with progressive cognitive impairment and cerebellar ataxia. Progressive neuronal loss, in particular the long-distance projection neurons of the cerebellar cortex, the Purkinje cells, underlies many of the pathological features observed in NPC1. Miglustat (a glycosphingolipid synthesis inhibitor) has been approved in the European Union and multiple other countries for the treatment of NPC1, it has not been approved by the FDA and its impact on disease progression is limited. 5, 6 Very little is known about the cellular death mechanisms leading to neuronal loss in NPC1, and thus the potential efficacy of cell death inhibitors remains unexplored. Recent in vitro studies have demonstrated defective autophagy in cellular models of NPC1 (fibroblasts and induced pluripotent stem (iPS) cell-derived neurons) 7, 8 and mouse models of NCP1 disease. 7, 9 Increased DNA damage demonstrated by both terminal deoxynucleotidyl transferase dUTP nick end labelling staining and electron microscopy, as well as increased expression of genes associated with death receptor signalling have been described in brain tissue from Npc1-mutant mice. 10 Consistent with the understanding of programmed cellular death at that time, it was concluded that neuronal death was due to apoptosis. 11 Based on this observation, Erickson and Bernard 11 evaluated the therapeutic potential of inhibiting caspase-dependent cell death using minocycline and transgenic expression of Bcl-2. Neither approach was effective in delaying the onset of neurological signs nor increasing lifespan in Npc1 − / − mice, thus this group concluded that neuronal loss in NPC1 is not due to apoptosis. Minocycline is a caspase 1 inhibitor, 11 and thus in retrospect, these data argue against pyroptosis, rather than apoptosis, as the mechanism of cell death in NPC1. 12 Although caspasemediated apoptosis is the most commonly investigated mechanism of programmed cell death, several other types of programmed cell death can occur. [13] [14] [15] Specifically, in the absence of caspase involvement, the most common pathway is necroptosis. [13] [14] [15] [16] In fact, Erikson and Bernard 11 noted that prior pathological studies 17, 18 suggested that neuronal loss in NPC1 might be due to necrosis rather than apoptosis. The inconclusive findings involving inhibition of apoptosis (Bcl-2 transgenic) and pyroptosis (minocycline), along with the pathological studies suggesting 'necrosis', led us to investigate the possible involvement of necroptosis in NPC1.
Although descriptions of caspase-independent programmed cell death were previously described, 19 necroptosis was initially delineated by Degterev et al. 20 Necroptosis is mediated by a heterologous protein complex known as the necrosome, which is a multiprotein complex, which includes the two protein kinases, receptor interacting protein kinase 1 (RIP1) and receptor interacting protein kinase 3 (RIP3). 14, 15 These two kinases are integral to the necrosome and regulate its function. 14, [19] [20] [21] Activation of the necrosome increases permeability of the plasma membrane with the subsequent leakage of intracellular contents. This in turn activates an inflammatory 'danger' or 'damage' signal thus accounting for necrosis-associated inflammation. 16 There is increasing evidence that necroptosis may contribute to neuronal death in neurodegenerative disorders, including Gaucher disease, 22 Huntington disease, 23 and amyotrophic lateral sclerosis. 24 The signalling cascades leading to the establishment of the necrosome can be inhibited by small molecules, including necrostatin-1 (Nec1), an allosteric RIP1 inhibitor. 20 Treatment with Nec1 was reported to be neuroprotective in NMDAmediated excitotoxicity 25 and cerebral ischemia. 26 Furthermore, it has been shown to be efficacious to target the necroptosis pathway in mouse models of Huntington disease 23 and amyotrophic lateral sclerosis. 24 In this paper, we investigate the role of necroptosis in NPC1 and evaluate the potential of inhibiting necroptosis as a therapy for NPC1.
Results
Decreased viability in NPC1-mutant fibroblasts. We determined the in vitro viability of fibroblasts derived from well-characterized NPC1 subjects being followed in a natural history trial at the National Institutes of Health (NCT00344331), using a panel of NPC1 fibroblasts representing the NPC1 phenotypic spectrum (Table 1) . Ageadjusted neurological severity scores (AANSSs) ranged from 0 to 7.7 using the NIH Neurological Severity Score. 27 Figure 1a ). Mean percentage of trypan blue-stained cells for two control lines was 5.2 ± 1.2. In contrast, fibroblasts from subjects with an AANSSo1.5 had a mean value of 7.8 ± 0.6 (n = 5, Po0.001) and from subjects with an AANSS41.5 had a mean value of 15.6 ± 1.1 (n = 5, Po0.001). The relationship between trypan blue-positive cells and AANSS is shown in Figure 1b . A series of experiments were performed to exclude apoptosis as the mechanism underlying the increased cell death rate of NPC1 fibroblasts. Control and NPC1 fibroblasts were double stained with Annexin-V and propidium iodide (PI) and analysed by flow cytometry. Annexin-V is an apoptosis marker that labels phosphatidyl serine, and PI labels dead cells with permeabilized plasma membranes. An increase in the fraction of Annexin-V-positive/PI-negative cells is consistent with apoptosis. We observed no difference in the fraction of Annexin-V-positive/PI-negative cells in control (7.0 ± 1.1%), NPC1 AANSSo1.5 (6.4 ± 4.6%), or NPC1 AANSS41.5 (2.8 ± 0.2%) control samples. Furthermore, using DAPI staining, we did not observe a significant difference in the ratio of condensed nuclei reported to the total number of nuclei per optic field when comparing control (0.8 ± 0.6%), NPC1 AANSSo1.5 (0.2 ± 0.1%), or NPC1 AANSS41.5 (0.3 ± 0.3%) fibroblast lines. Western blotting analysis demonstrated that neither caspase 3 nor caspase 8 protein levels were increased in NPC1 fibroblasts (Figure 1c ). These data argue against increased apoptosis as the mechanism underlying the increased cellular death observed in NPC1 fibroblasts.
We next explored whether increased necroptosis was observed in cultured NPC1 fibroblasts. Consistent with necroptosis, western blotting analysis demonstrated increased expression of RIP1 and RIP3 protein in NPC1 fibroblasts compared with control fibroblasts (Figure 1c) . Increased protein expression of mixed lineage kinase domain-like (MLKL), a third component of the necrosome complex, was not observed in whole protein lysates. The relationship between relative RIP1, RIP3, MLKL, caspase 3, and caspase 8 average protein relative expression levels and AANSS is shown in Supplementary Figure S2 . Only RIP1 levels appear to increase with increased AANSS, and similar to what was Necrosome assembly was evaluated by using either anti-RIP1 or anti-RIP3 to immunoprecipitate the necrosomal complex and subsequent probing by western blotting using either anti-RIP1 or anti-RIP3 (Figure 1d ). When the necrosomal complex was immunoprecipitated using anti-RIP1, a strong interaction with RIP3 and MLKL was clearly observed in NPC1 fibroblasts. Similarly, when the necrosomal complex was immunoprecipitated using anti-RIP3, increased levels of RIP1 and MLKL were observed in NPC1 fibroblasts compared with control fibroblasts. Of note, the formation of the necrosomal complex appeared to be more prominent in fibroblast lines from subjects with AANSS ⩾ 1.5 (NPC21, 24, 25, 57, and 76). Increased activation of the necroptotic pathway was also observed in neuronal precursors derived from NPC1 iPS cells (Figure 1e ). Accumulation of necrosomal proteins was observed in NPC1-derived neuronal stem cells, and consistent with our fibroblast data, immunoprecipitation (IP) followed by western blotting analysis demonstrated increased interaction of RIP1 and RIP3 in NPC1 neuronal stem cells.
Necroptosis in cerebellar tissue from Npc1-mutant mice and NPC1 subjects. We next explored whether increased activation of the necroptotic pathway could be observed in +/+ and Npc1 − / − mice evaluated by western blotting analysis. Expression of RIP1, RIP3, caspase 3, and caspase 8 from 3 to 11 weeks was characterized. Experiments were repeated on six independent animals. GAPDH was used as a loading control. (h) Immunoblot (IB) analysis of RIP1 and RIP3 immunoprecipitated with either anti-RIP1 (IP RIP1) or anti-RIP3 (IP RIP3) on mouse cerebellar lysate (n = 6). IP with nonspecific IgG serves as a negative control. Results of two separate IPs (#1 and #2) are shown. (i) RIP1, RIP3, caspase 3, and caspase 8 expression evaluated by western blotting in age-matched patient cerebellar lysate cerebellar tissue from Npc1-mutant mice. Gene expression of Ripk3, and to a lesser extent Ripk1, progressively increased from 3 weeks of age until 11 weeks of age when these mice are typically euthanized owing to significant neurological impairment per Animal Care and Use Committee guidelines (Figure 1f) . Western blotting analysis of total protein lysates from control and mutant mouse cerebellar tissue demonstrated increasing RIP1 and RIP3 protein in Npc1-mutant mice after 5 and 5 weeks of age, respectively (Figure 1g) . No change in the protein levels of either caspase 3 or 8 were observed by western blotting (Figure 1g) . Assembly of the necrosomal complex was confirmed by IP of the necrosome using either anti-RIP1 or anti-RIP3 followed by immunoblotting for RIP3 or RIP1, respectively. Increased interaction of RIP1 and RIP3 was observed in cerebellar tissue from 7-week-old Npc1 − / − mice compared with Npc1 +/+ tissue (Figure 1h) .
Western blotting analysis of protein lysates derived from cerebellar tissue from three NPC subjects clearly demonstrated increased protein expression of RIP1 in human brain tissues in two of the three samples and of RIP3 in all three of the samples relative to age-matched control human cerebellar cortex samples (Figure 1i ). Consistent with necroptosis and not apoptosis being activated in NPC1 cerebellar tissue, caspase 3 and caspase 8 protein levels were not increased relative to control tissue.
Inhibition of necroptosis increases NPC1 fibroblast viability. After establishing necrosomal activation in NPC1, we then evaluated whether inhibition of necroptosis in NPC1 fibroblasts would increase cell viability. No effect on cell viability was observed for control lines when treated with the RIP1 inhibitor, Nec1 (Figure 2a and Supplementary Figure S3 ). Treatment of NPC1 fibroblasts from subjects NPC5 (AANSS 1.4) and NPC25 (AANSS 6) with 1 μM Nec1 significantly (Po0.05) decreased the percentage of trypan blue-stained cells in both NPC1 cell lines (Figures 2b and c) . This decrease in trypan blue staining was not observed when the subject cell lines were treated with an inactive analogue of Nec1, Necrostatin-1 inactive (Nec1i). Treatment of NPC1 fibroblasts with Nec1 had no apparent effect on cell morphology or filipin staining (data not shown). Filipin is a fluorescent antibiotic that is used to demonstrate increased lysosomal storage of unesterified cholesterol in NPC1 cells. Suppression of either RIP1 or RIP3 expression utilizing siRNAs resulted in significant suppression of cell death (Po0.05) in both NPC5 and NPC25 (Figures 2b and c) . Decreased expression of RIP1 and RIP3 protein in siRNAtreated fibroblasts was demonstrated by western blotting (Supplementary Figure S4) . Figures S3 and S5 ). Efficacy of Nec1 was also evaluated in fibroblast cultures treated with TNFα to induce necroptosis. When evaluating the percentage of trypan blue-positive cells, Nec1 reduced the cytotoxic effects of TNFα from 67.3 ± 4.1 to 25.9 ± 6.1%, 44.3 ± 3.5 to 18.7 ± 3.4%, and 56.0 ± 5.9 to 16.5 ± 2.9% for control (Po0.01), AANSSo1.5 (Po0.01), and AANSS41.5 (Po0.01) lines, respectively (data not shown). These data were confirmed by measuring LDH release into the medium (Supplementary Figure S5) .
As a control, we also evaluated the in vitro effects of inhibition of apoptosis using Z-VAD-FMK, a broad caspase inhibitor. No effect on cell viability was observed for control lines (Figure 2a and Supplementary Figure S3) ; however, exposure of NPC25 cells to Z-VAD-FMK actually decreased cellular viability in NPC25 (Figure 2, Po0.05 ). This later observation is consistent with the known crosstalk between caspase-dependent and -independent cellular death and the role of caspases in suppressing necroptosis.
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Figure 2 
Treatment of Npc1
− / − mice with Nec1 delays the onset of disease manifestations and prolongs lifespan. Based on our data demonstrating increased cellular viability in NPC1 fibroblasts treated with Nec1, we tested whether in vivo treatment of Npc1 − / − mice with Nec1 would impact the NPC1 phenotype. Npc1 +/+ and Npc1 − / − mice were treated with either Nec1, Nec1i, or vehicle (phosphate-buffered saline (PBS)) administered every 2 days by intraperitoneal (i.p.) injection initiated after weaning at 3 weeks of age. Nec1 and Nec1i were studied at 90 and 180 mcg/kg. Control mice did not demonstrate any adverse drug-related physiological or behavioural side effects at either dose level. Relative to vehicle-treated Npc1 − / − mice, lifespan was increased in Npc1-mutant mice by an average of 10 ± 4 (Po0.05) and 13 ± 4 days (Po0.05) when treated with 90 and 180 mcg/kg of Nec1, respectively (Figure 3a) . No survival benefit was observed in Npc1-mutant mice treated with Nec1i (P = 0.72) nor was there a significant difference between the two Nec1 doses (P = 0.12). Signs consistent with NPC1 disease progression were also delayed in Nec1-treated Npc1 +/+ mice, a significant decrease (Po0.05) in rearing activity was observed after 8 weeks of age in PBS-and Nec1i-treated Npc1 − / − mice. In contrast, a significant decrease in rearing activity was not observed until Figures S7 and S8) . In all three cases, there was preservation of lobule X calbindin D-positive cerebellar Purkinje cells but absence of cerebellar Purkinje cells in the anterior lobules. These data are consistent with a delay, but not prevention, of cerebellar Purkinje cell loss in Npc1-mutant mice.
Discussion
NPC1 is a lysosomal storage disorder characterized by the endolysosomal storage of unesterified cholesterol and other lipids, such as sphingosine and glycosphingolipids. 1, 29 The progressive neurological manifestations of NC1 are ultimately due to loss of neurons. In particular, the ataxia, which is a prominent neurological symptom of the disorder, is due to loss of cerebellar Purkinje cells. The cascade of events precipitated by the endolysosomal accumulation of unesterified cholesterol and lipids has not been fully delineated. Prior work has demonstrated that neuroinflammation, 30 mitochondrial dysfunction, 31 impaired axonal transport, 32 impaired lysosomal calcium homeostasis, 4 and oxidative stress 31, 33 are likely contributors to the pathological cascade that ultimately results in neuronal loss. In this paper, via a series of in vitro and in vivo experiments, we demonstrate that activation of the necroptotic pathway contributes to neuronal death in NPC1 and that inhibition of RIP1 function may have therapeutic benefit.
Necroptosis is a specific mechanism of programmed cell death that has been shown to be associated with neurodegenerative disorders 21 and with Gaucher disease, 22 a lysosomal storage disorder like NPC1. Necroptosis is initiated by formation of the necrosome, a multiprotein complex containing RIP1 and RIP3 kinases.
14 In addition to being a regulator of the necrosome, RIP1 regulates inflammatory signalling initiated by activation of TNFα and Toll-like receptors. 16 Notably, necroptosis appears to be a cellular death mechanism present in neurodegenerative disorders with neuroinflammation. 18, 23, 24 Neuroinflammation has been described in NPC1 and has been postulated to contribute to NPC1 disease progression, 30, 34, 35 and prior pathological studies reporting necrosis suggested that necrosis was contributing to neuronal death in NPC1 brain tissue. 36 In this manuscript, we utilized a series of in vitro experiments to demonstrate activation of necroptosis in NPC1 fibroblasts and iPS cell-derived neuronal precursors. Of note, activation of the necroptotic pathway positively correlates with disease severity. We also demonstrated that the necroptotic pathway is activated in both NPC1-mutant mouse and human patient brain tissue, thus strongly suggesting that necroptosis has a pathological role in NPC1. RIP1 is the major regulator of necroptosis 20 and its activity can be inhibited by Nec1. Inhibition of RIP1 by Nec1 is effective in prolonging cell viability, decreasing cellular spontaneous death in NPC1 both in vitro and in vivo. Treatment of Npc1 − / − mice with Nec1 resulted in delayed cerebellar Purkinje cell loss, delayed progression of neurological manifestations, and significantly prolonged lifespan. These findings were not observed when Npc1 − / − mice were treated with vehicle alone or Nec1i, an inactive variant of Nec1. Lifespan increased from 73.8 ± 1.3 days to 83.2 ± 1.5 (13%) and 86.9 ± 1.4 (18%) days in mice treated with 90 and 180 mcg/kg of Nec1, respectively. Although significant, the survival benefit we observed in the NPC1 mouse model with Nec1 is less than that observed with either miglustat 37 or 2-hydroxypropyl-β-cyclodextrin. 38, 39 We suspect that this modest increase in lifespan may be due to sub-optimal pharmacokinetic properties of Nec1 and the dosing frequency used in this study. Nec1 has a half-life of approximately 1 h, 40 and i.p. injections every 2 days, although practical from the standpoint of animal care, is not optimal. Supporting the contention that Nec1 therapy was suboptimal owing to dosing and pharmacokinetic properties, we observed only a partial decrease of necrosome formation in treated mice (Figure 3c ) and observed no significant difference in lifespan when dosing with either 90 or 180 mcg/kg of Nec1. RIP1 inhibitors with better pharmacokinetic properties are being developed, [41] [42] [43] [44] and these inhibitors will be the subject of further study. In addition to inhibiting RIP1, Nec1 also inhibits indoleamine 2,3-dioxygenase (IDO), which catalyses the ratelimiting step of tryptophan catabolism and an immune regulator. 45 However, inhibition of IDO unlikely contributes significantly to the observed benefits of Nec1 therapy. The EC50 for inhibition of IDO by Nec1 is approximately 115 μM. 44 At the high dose of 180 μg/kg, the highest theoretical maximum concentration (Cmax) in blood is 2.25 μg/ml (or 8.7 μM) after IV bolus injection, assuming a blood volume of 80 ml/kg (i.e., 8% body weight). The Cmax after IP injection would be lower than that after IV injection and distribution of the drug beyond the vascular compartment would further lower predicted drug levels. Thus, the likelihood of inhibition of Nec1 on IDO would be remote at the dose levels of 90 and 180 μg/kg used in this study. An alternative mechanism to inhibiting necroptosis via knockdown of RIP1 activity would be inhibition of TNFα production. This is an unlikely mechanism in NPC1 as increased production of TNFα has not been observed in vivo or in vivo. 46 
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Targeting the RIP1/RIP3 pathway has been demonstrated to be a potential therapeutic option in other neurodegenerative diseases (e.g., Gaucher, 22 Huntington 23 ) as well as in a rodent stroke models. 47, 48 In this paper, we demonstrate that necroptosis is involved in the NPC1 pathogenic cascade, and our data indicate that inhibition of RIP1 may have a therapeutic role in treating patients with NPC. Necroptosis is a late, if not the final, step in the NPC1 pathogenic cascade, thus it is not likely that this therapy will be a stand-alone therapy. However, as part of a combined therapy, inhibition of necroptosis in NPC1 may contribute significantly to the treatment of this progressive neurodegenerative disease. RIP1 inhibitors with better pharmacological properties remain to be tested for efficacy in the NPC1 mouse model. In addition, given the clear involvement of the necrosome in NPC1 pathology, inhibition of RIP3 or combined RIP1/RIP3 inhibition should be evaluated for efficacy in NPC1. To our knowledge, this is the first report of the potential benefit of RIP1 inhibition in a lysosomal storage disorder. Work in the Gaucher disease model demonstrated potential efficacy of RIP3 inhibition. 22 Given that the pathological processes leading to neuronal loss in lysosomal storage disorders are often nonspecific, we postulate that RIP1 or combined RIP1/RIP3 inhibition may also prove effective in significantly delaying neurodegeneration in other lysosomal storage disorders.
Materials and Methods
Human subject and animal protections. NPC1 fibroblast cell lines were established as part of a NICHD Institutional Review Board-approved clinical protocol to study the Natural History of NPC (NCT00344331). Guardian permission and, when possible, subject consent/assent were obtained. Animal work was conducted under an approved NICHD Animal Care and Use Committee-approved protocol. Postmortem human cerebellar tissues were obtained from the NICHD Brain and Tissue Bank.
Fibroblast lines and iPS cells. NPC fibroblast lines were established from skin biopsies. Control lines GM05659C (WT1) and GM03468A (WT2) were obtained from the NIGMS Human Genetic Mutant Cell Repository (Coriell, NJ, USA). Cells were maintained in DMEM (Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (Omega Scientific, Offenburg, Germany), L-Glutamine (Life Technologies), and penicillin/streptomycin (Life Technologies) and grown on tissue culture plates (BD, San Diego, CA, USA) at 37°C 5% CO 2 in a humidified incubator. iPS cells from WT GM05659, NPC6, NPC9, and NPC GM03123 cells were generated, differentiated, and maintained in culture as previously described. 49 Cell viability assays. Cell viability was measured using a trypan blue exclusion assay. Cells in suspension were collected and mixed with 0.4% trypan blue solution (Life Technologies) at a 1 : 1 ratio and 10 μl of the cell suspension was then loaded onto the TC10 System (Bio-Rad Laboratories, Hercules, CA, USA) counting slide to quantify the number of viable cells. The leakage of LDH, an intracellular cytoplasmic enzyme, into the medium is a marker of plasma membrane integrity. Loss of plasma membrane integrity is a hallmark of necrosis. Briefly, a reaction mixture of 0.2 mM NADH (Sigma Aldrich, St. Louis, MO, USA) and 0.36 mM sodium pyruvate (Sigma Aldrich) was dissolved in Krebs-Henseleit (K-H) buffer containing 2% bovine serum albumin. The K-H buffer is composed of 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO 4 , 1.25 mM CaCl 2 , 1.2 mM KH 2 PO 4 , and 24 mM NaHCO 3 (pH 7.4). Ten microliters of cell supernatant and 190 μl of reaction mixture were mixed well in 96-well plates prior to spectrophotometric kinetic readings. Owing to the differences in the absorption spectra of NADH and NAD + , changes in the NADH concentration can be detected at 340 nm. The decrease in absorbance measured every minute over a 10-min period represents the activity of LDH. One unit of LDH activity is defined as the quantity for oxidation of 1 μmol NADH per minute; the LDH activity of cell supernatant was expressed in units per liter (Unit/l). We also monitored loss of plasma membrane integrity by measuring SYTOX Green (Molecular Probes-Invitrogen, Eugene, OR, USA) Hoechst 3342 (Molecular Probes) double staining by immunofluorescence.
Apoptosis assay. To examine the percentage of apoptotic cells, the measurements were carried out using FACS Calibur (BD, San Diego, CA, USA) or fluorescence microscopy. Cells were trypsinized and stained in solution with Annexin V-fluorescein and PI for 20 min at 25°C in the dark using the FITC Annexin-V apoptosis Detection Kit I (BD). After washing with ice-cold PBS, fluorescence was measured by flow cytometry. For assessment of apoptosis by fluorescence microscopy, fibroblasts were stained with DAPI and mounted on glass slides using Mowiol (Calbiochem, San Diego, CA, USA). For each experiment and each condition, at least 200 cells were scored in a blinded manner by counting the percentage of condensed nuclei in five random fields for each condition.
Animal breeding, treatment and tissue collection. Npc1 +/ − mice were intercrossed to obtain Npc1 +/+ and Npc1 − pc mice. Pups were weaned 3 weeks after birth; water and normal mouse chow were available ad libitum. Genotyping PCR was performed using tail DNA. 50 Mice were euthanized at 1, 3, 5, 7, 9, and 11 weeks of age. Cerebellum were collected from both mutant and control animals and immediately frozen on dry ice. Npc1 +/+ and Npc1 −/− mice were randomly placed in one of the treatment groups: Vehicle (PBS), Nec1 (PubChem CID 2828334; Millipore, Billerica, MA, USA), or Nec1i (PubChem CID 5371761; Millipore). Treatment was initiated at 3 weeks. Mice were treated every 2 days by i.p. injection with PBS or 90 mcg/kg Nec1, 180 mcg/kg Nec1, 90 mcg/kg Nec1i, or 180 mcg/kg Nec1i. After 4 weeks of treatment, 10 animals per group were euthanized and the other 10 were euthanized when survival end point criteria were reached, which were: hunched posture and reluctance to move about the cage, inability to remain upright when moving forward, and weight loss 430% of peak weight. Age-matched Npc1 +/+ -injected animals were euthanized for comparison. Mice were euthanized in a CO 2 chamber and then transcardially perfused with PBS for biochemical and molecular analysis or transcardially perfused with 4% paraformaldehyde solution to fix the tissue prior to pathological analysis.
Immunohistochemistry. Brain cerebellar tissue was processed as described. 34 Mice were killed at 7 weeks by CO 2 asphyxiation and transcardially perfused with ice-cold 4% paraformaldehyde in PBS, pH 7.4. The brains were postfixed in 4% paraformaldehyde solution for 24 h and then cryoprotected in 30% sucrose. Cerebellar tissues were cryostat-sectioned parasagittally (20 mcm) and floating sections were collected in PBS with 0.25% Triton × 100. Sections were incubated overnight at 4°C with rabbit anti-calbindin (1 : 2000, Swant, Marly, Switzerland) and DAPI (1 : 5000, Invitrogen, Carlsbad, CA, USA), detected using Dy-Light-594 goat anti-mouse IgG (Vector, Burlingame, CA, USA).
RNA extraction. Total RNA was extracted from mouse cerebellum tissues, using TRIzol reagent (Life Technologies), followed by purification with Qiagen RNeasy Mini Columns (Qiagen, Hilden, Germany). For gene expression analysis by real-time qPCR, the quality and the quantity of RNA were assessed using NanoDrop (Thermo Scientific, Inc., Pittsburgh, PA, USA). One mcg of total RNA was reversetranscribed to obtain cDNA using a High-Capacity cDNA Archive Kit, according to the manufacturer's instructions (Life Technologies). The following TaqMan assays were used to assess the relative expression level of: Ripk1 (Mm00436354_m1), Ripk3 (Mm01319233_g1), and Gapdh (Mm03302249_g1). Amplifications were performed in 96-well plates with an Applied Biosystems 7300 real-time PCR system (Carlsbad, CA USA). Each sample was analysed in triplicate, using 50 ng of total cDNA for each reaction, as described. 51 Protein extraction and western blottings. Total proteins were extracted from cells, patient samples and mouse tissues using RIPA buffer (50 mM Tris-HCl, pH7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 nM EDTA, 40 mM NaF, 0.2 mM Na 3 VO 4 ) with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Protein amounts were determined using the BCA assay (Bio-Rad Laboratories). Protein lysates (typically 5-20 μg) were loaded onto a 4-12% gradient NuPAGE Gel (Invitrogen, Carlsbad, CA, USA), and electrophoresis was carried out at a constant 120 V. Protein transfer was performed using the iBLOT dry transfer setup (Life Technologies) according to the manufacturer's protocol. Following transfer, nitrocellulose membranes were incubated in a 2% BSA and PBS 0.1% Tween 20 blocking buffer for 1 h at room temperature, followed by incubation with the primary antibody at 4°C overnight.
After the initial incubation, the membrane was rinsed and incubated with the appropriate secondary antibody for 1 h at room temperature. Membrane development was carried out using the Bio-Rad Chemiluminescence Detection Kit (Hercules, CA, USA). Primary antibodies used include: hRIP3 (1 : 1000 ) were normalized to GAPDH using the ImageLab4.1 software (Bio-Rad Laboratories).
Rearing evaluation. Spontaneous activity of each mouse was recorded weekly until reaching the late humane end point (loss of 1 g body weight within 24 h) as previously described. 34 Briefly, rearing was recorded manually for 5 min (the number of times the mouse reared on its hind legs with or without support of the cage wall).
Statistical analysis. Results were presented as mean ± S.E.M. MannWhitney U-test was used to compare between two groups. Differences were considered to be significant with P-values of o0.05. Statistical calculations were performed with the GraphPad Prism software (San Diego, CA, USA).
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